DiaCarta is a precision diagnostic company that specializes in advanced cancer patient management solutions, utilizing proprietary technologies to enhance the detection and monitoring of genetic alterations. Their innovative XNA technology significantly improves the sensitivity and specificity of traditional genomic platforms, enabling the detection of rare genetic changes in both tissue and liquid biopsy samples. This technology is particularly beneficial for early-stage cancer detection and monitoring minimal residual disease (MRD). Additionally, DiaCarta's isobDNA™ technology offers a unique approach by amplifying signals rather than requiring DNA extraction, thus preserving valuable sample material and providing accurate results comparable to conventional PCR methods.

The company's product offerings include a range of diagnostic tests such as RadTox™, ColoScape™, and Oncuria®, which are designed to monitor tumor responses and detect various cancers. DiaCarta also provides tests for infectious diseases, including HPV and MonkeyPox, showcasing their commitment to comprehensive healthcare solutions. With a focus on research and development, strategic partnerships, and global expansion, DiaCarta aims to advance precision medicine and improve patient care through its innovative diagnostic technologies.

United States

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit http://www.diacarta.com.

DiaCarta

Company Details